Biomime Biosorbable Polymer Sirolimus-ELuting Stent in alL-comers patIeNts Treated With Percutaneous Coronary Interventions: the BELLINI Registry
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 250
- 试验地点
- 1
- 主要终点
- target vessel revascularization
研究概览
简要总结
Biomime stent is a novel sirolimus-eluting stent (SES) (Meril Life Sciences Pvt. Ltd., Gujarat, India) with an ultra-thin stent platform (65 μm) and a biodegradable polymer licensed for the treatment of de novo coronary lesions. However no data regarding the efficacy and safety of this stent in an "all-comers" patient population treated with percutaneus coronary interventions (PCI) have been published so far. In this registry the investigators aimed to collect clinical and angiographic information about an extensive "all-comers" employ of this novel stent.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •any coronary artery disease treated with percutaneous coronary intervention and a Biomime stent
排除标准
- •patients <18 years old
结局指标
主要结局
target vessel revascularization
时间窗: 1 year
rate of target vessel percutaneous or surgical reintervention for recurrent symptoms or inducible ischemia at follow up testes
次要结局
- cardiac death(1 year)
- reinfarction(1 year)
- death from any cause(1 year)
- target lesion revascularization(1 year)
研究者
Lupi Alessandro
Dr Alessandro Lupi
Azienda Ospedaliero Universitaria Maggiore della Carita